CMS, Heart attacks and Technology - Cardiovascular Update

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

CMS

Heart attacks

Technology

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

MARCH 7, 2024

Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement. vs. 13.2%, respectively).

Heart Failure

Heart Failure Biomarkers CMS Reimbursement

Bridging the Gap: Enhancing Stroke Recovery Through Digital Health Solutions

DAIC

JUNE 4, 2024

I had had a heart attack previously. Technology tools are becoming more sophisticated, bidirectional and disease-specific, and are being designed with home care in mind. After the stroke, I had new prescriptions, and this was the first obstacle for me. I couldn’t dispense my medications into daily doses.

Stroke

Stroke Strokes Innovation Research

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Bridging the Gap: Enhancing Stroke Recovery Through Digital Health Solutions

Stay Connected